Perrigo has transferred a portfolio of preclinical assets gained through its December 2013 acquisition of Elan Corp. to Imago Pharmaceuticals. Perrigo will receive an upfront payment in addition to development-related milestones and royalties on future sales.   Perrigo’s chairman and chief executive officer, Joseph C. Papa said, “This transaction demonstrates our commitment to focusing our development efforts to those projects where we can best fulfill our ‘Quality, Affordable ...